Oral anticoagulants and status of antidotes for the reversal of bleeding risk

Clinical and Applied Thrombosis/Hemostasis

Volumn 21, Issue 2, 2015, Pages 105-114

  Ebright, Joseph ^a   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

andexanet alfa; antidote; apixaban; bleeding; dabigatran; direct thrombin inhibitor; factor Xa inhibitor; fresh frozen plasma; prothrombin complex concentrate; reversal agents; rivaroxaban; vitamin K; vitamin K antagonist; warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTIDOTE; BLOOD CLOTTING FACTOR 10A INHIBITOR; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; HUMAN; META ANALYSIS (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; CHEMICALLY INDUCED; HEMORRHAGE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIDOTES; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS;

EID: 84923032915     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029614545211     Document Type: Article

References (44)

1. Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol. 2008 ; 28 (3). 370-372
2. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006 ; 114 (2). 119-125
3. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001 ; 285 (18). 2370-2375
4. Kim MJ, Huang SM, Meyer UA, Rahman A, Lesko LJ. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol. 2009 ; 49 (2). 138-146
5. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011 ; 32 (19). 2387-2394
6. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 ; 361 (12). 1139-1151
7. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009 ; 361 (24). 2342-2352
8. Zivelin A, Rao LV, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest. 1993 ; 92 (5). 2131-2140
9. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation): developed in collaboration with the North american society of pacing and electrophysiology. J Am Coll Cardiol. 2001 ; 38 (4). 1231-1266
10. Breckenridge A. Oral anticoagulant drugs: pharmacokinetic aspects. Semin Hematol. 1978 ; 15 (1). 19-26
11. O'Reilly RA. Vitamin K and the oral anticoagulant drugs. Annu Rev Med. 1976 ; 27: 245-261
12. Kelly JG, O'Malley K. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet. 1979 ; 4 (1). 1-15
13. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol. 1998 ; 45 (6). 525-538
14. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009 ; 15 (3). 244-252
15. COUMADIN(R) oral tablets, intravenous injection, warfarin sodium oral tablets, intravenous injection [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2011. http://packageinserts.bms.com/pi/pi-coumadin.pdf. Accessed March 18, 2014.
16. Forfar JC. Prediction of hemorrhage during long-term oral coumarin anticoagulation by excessive prothrombin ratio. Am Heart J. 1982 ; 103 (3). 445-446
17. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995 ; 333 (1). 11-17
18. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 ; 141 (2 suppl). e152S - e184S
19. Sarode R, Matevosyan K, Bhagat R, Rutherford C, Madden C, Beshay JE. Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage. J Neurosurg. 2012 ; 116 (3). 491-497
20. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004 ; 126 (3 suppl). 204S - 233S
21. Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS. Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy. 2000 ; 20 (10). 1159-1166
22. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003 ; 163 (20). 2469-2473
23. Ageno W, Garcia D, Aguilar MI, et al. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. Am J Hematol. 2009 ; 84 (9). 584-588
24. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med. 2005 ; 33 (4). 721-726
25. Frumkin K. Rapid reversal of warfarin-associated hemorrhage in the emergency department by prothrombin complex concentrates. Ann Emerg Med. 2013 ; 62 (6). 616-626
26. Chapman SA, Irwin ED, Beal AL, Kulinski NM, Hutson KE, Thorson MA. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Ann Pharmacother. 2011 ; 45 (7-8). 869-875
27. Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R. Suboptimal effect of a 3-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009 ; 49 (6). 1171-1177
28. Efficacy and Safety Study of BERIPLEX P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy. http://clinicaltrials.gov/ct2/show/study/NCT00708435?sect=Xbdf3g986015&view=results. Accessed March 10, 2014.
29. Pabinger I, Brenner B, Kalina U, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008 ; 6 (4). 622-631
30. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 ; 365 (10). 883-891
31. ELIQUIS® (apixaban) tablets for oral use [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2014. http://packageinserts.bms.com/pi/pi-eliquis.pdf. Accessed March 18, 2014.
32. XARELTO (rivaroxaban) tablets, for oral use [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc; 2011. http://www.xareltohcp.com/sites/default/files/pdf/xarelto-0.pdf#zoom=100. Accessed March 18, 2014.
33. Alexander JH, Lopes RD, Thomas L, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014 ; 35 (4). 224-232
34. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 ; 364 (9). 806-817
35. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011 ; 124 (14). 1573-1579
36. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013 ; 19 (4). 446-451
37. Crowther M, Kitt M, Lorenz T, et al. A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors. XXIV Congress of the International Society on Thrombosis and Haemostasis ; Amsterdam, the Netherlands ;..
38. Potola Pharmaceuticals Inc. Portola Pharmaceuticals Announces First Phase 2 Results Demonstrating Extended Duration Infusion With Andexanet Alfa (PRT4445) Provides Prolonged Reversal of Anticoagulation Activity of Factor Xa Inhibitor Eliquis(R); 2013. http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsArticle&ID=1864273&highlight=. Accessed March 25, 2014.
39. Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011 ; 123 (13). 1436-1450
40. PRADAXA® (dabigatran etexilate mesylate) capsules for oral use [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2013. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed March 18, 2014.
41. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev. 2007 ; 4: CD001886 CD001886
42. Wanek MR, Horn ET, Elapavaluru S, Baroody SC, Sokos G. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann Pharmacother. 2012 ; 46 (9). e21
43. Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013 ; 61 (3). 487-489
44. Alikhan R, Rayment R, Keeling D, et al. The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J. 2014 ; 31 (2). 163-168